Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Backing For Procolaran In CHF May Prove Lucrative For Servier

This article was originally published in The Pink Sheet Daily

Executive Summary

If NICE’s backing for Servier’s heart drug Procolaran does spread across Europe, then the resulting returns may offset some of financial pain the French group is set to feel in coming years.

You may also be interested in...



Double-Jointed Partnership With Servier Could Jumpstart Amgen’s CV Portfolio

Amgen gets U.S. rights to a pair of heart failure candidates from the French firm, with the lead candidate already approved in Europe and likely to be filed quickly at FDA. Meanwhile, Servier obtains EU commercialization rights to a CV drug partnered between Amgen and Cytokinetics.

Servier’s EU Nightmare Continues As Commission Moves To Shut Down Disputed IP Practices

The European Commission’s allegations against Servier for alleged patent abuses could help to clarify the law in this area for original product manufacturers in the long term.

France Proposes Mediator Injury Compensation Program, Pressuring Servier To Fund It

Proposal would also shield French regulatory agency that approved the diabetes drug from victims' lawsuits.

Topics

Related Companies

UsernamePublicRestriction

Register

PS073552

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel